Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Google defeats US bid to force ad tech sale
BTIG Starts Corvus Pharmaceuticals (CRVS) at Buy
April 19, 2016 6:47 AM EDTBTIG initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $22.00. Analyst Hartaj Singh is bullish on management and lead compound CPI-444.
"The company has two most important characteristics that we look for in early-stage biotech companies, (1)... More
Guggenheim Starts Corvus Pharmaceuticals (CRVS) at Buy
April 18, 2016 7:26 AM EDTGuggenheim initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.
Shares of Corvus Pharmaceuticals closed at $15.61 yesterday.
... MoreCredit Suisse Starts Corvus Pharmaceuticals (CRVS) at Outperform
April 18, 2016 6:39 AM EDTCredit Suisse initiates coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Outperform rating and a price target of $25.00.
Analyst V. Divan commented, "We see CRVS as a compelling earlystage immuno-oncology (I-O) opportunity that is relatively higher risk but that also offers a potentially high reward. CRVS's lead compound,... More
